Market closed

Acumen Pharmaceuticals/$ABOS

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About Acumen Pharmaceuticals

Acumen Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target what it believes to be a key underlying cause of Alzheimer's disease. The company's drug candidate, ACU193, is a subclass monoclonal antibody that selectively targets amyloid-beta oligomers.

Ticker

$ABOS
Trading on

Industry

Biotechnology

Employees

52

ABOS Metrics

BasicAdvanced
$96M
-
-$1.37
-0.07
-

$96M

-0.07

$5.09

$1.57

355K

10.426

10.06

13.747

13.807

-25.72%

-20.99%

-32.83%

0.44

0.44

-1.405

24.61%

-47.15%

What the Analysts think about ABOS

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Acumen Pharmaceuticals stock.

ABOS Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

ABOS Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ABOS

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Acumen Pharmaceuticals stock?

Acumen Pharmaceuticals (ABOS) has a market cap of $96M as of January 15, 2025.

What is the P/E ratio for Acumen Pharmaceuticals stock?

The price to earnings (P/E) ratio for Acumen Pharmaceuticals (ABOS) stock is 0 as of January 15, 2025.

Does Acumen Pharmaceuticals stock pay dividends?

No, Acumen Pharmaceuticals (ABOS) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Acumen Pharmaceuticals dividend payment date?

Acumen Pharmaceuticals (ABOS) stock does not pay dividends to its shareholders.

What is the beta indicator for Acumen Pharmaceuticals?

Acumen Pharmaceuticals (ABOS) has a beta rating of -0.07. This means that it has an inverse relation to market volatility.